Researchers report semuloparin data

A researcher at McMaster University and colleagues reported a meta-analysis of three Phase III trials comparing a venous thromboembolism (VTE) candidate from sanofi-aventis Group (Euronext:SAN; NYSE:SNY) to the company's marketed Lovenox enoxaparin to prevent VTE in patients undergoing major orthopedic surgery. The analysis found that the candidate, semuloparin, significantly reduced the composite rate of any VTE and all-cause mortality vs. Lovenox enoxaparin (13.4% vs. 17.6%). The analysis included 3,457 evaluable patients undergoing major orthopedic surgery in the SAVE HIP 1, HIP 2 and KNEE trials. Semuloparin is a dual inhibitor of Factor IIa and Xa. ...